Research reveals MZB1 CAR T cell therapy improves cytotoxicity in malignant B cells, suggesting broader applicability and enhanced efficacy via CAR enhancer.
Key Points
This research focuses on the development of MZB1-directed CAR T cell therapy for multiple myeloma and other B-cell malignancies.
Developed CAR T cells utilizing TCR-like antibodies recognizing intracellular MZB1 antigens.
Generated bispecific MZB1/BCMA CAR T cells with a novel CAR enhancer (CAR-E) for improved persistent expansion.
Conducted in vitro and in vivo assays to evaluate CAR T cell activity against tumor cells.
MZB1 CAR T cells demonstrated significant cytotoxicity against MZB1+ and HLA-A2+ multiple myeloma cells in vitro.
MZB1/BCMA CAR E T cells showed superior clearance of multiple myeloma tumors in vivo compared to other CAR T therapies.
High expression of MZB1 identified in Waldenström Macroglobulinemia, allowing for targeted treatment.